Avidity Partners Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Avidity Partners Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,000	Closed	-$8.35M	–	48
2025 Q4	$8.35M	Buy	+21,000	New	+$9.29M	2.41%	9
2024 Q3	–	Sell	-222,000	Closed	-$53.9M	–	83
2024 Q2	$53.9M	Sell	222,000 -21,000	-9%	-$3.32M	2.29%	12
2024 Q1	$36.3M	Buy	+243,000	New	+$40.5M	1.17%	32
2022 Q4	–	Sell	-288,500	Closed	-$57.7M	–	86
2022 Q3	$57.7M	Buy	+288,500	New	+$55M	1.17%	30
2022 Q1	–	Sell	-370,000	Closed	-$62.7M	–	94
2021 Q4	$62.7M	Sell	370,000 -57,000	-13%	-$10.6M	1.33%	26
2021 Q3	$80.6M	Buy	427,000 +232,000	+119%	+$43.5M	1.79%	17
2021 Q2	$33.1M	Sell	195,000 -232,969	-54%	-$34.1M	0.89%	41
2021 Q1	$60.4M	Buy	+427,969	New	+$64.4M	1.67%	19

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Avidity Partners Management's ALNY Position: Q1 2026 in Review

Avidity Partners Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 21,000 shares — an estimated $8.35M sold.

Avidity Partners Management first reported a position in ALNY in Q1 2021 and held it in 8 quarters. The position peaked at $80.6M in Q3 2021. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Avidity Partners Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Avidity Partners Management sold 21,000 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $8.35M.
Avidity Partners Management first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 8 quarters.
Avidity Partners Management's Alnylam Pharmaceuticals position peaked at $80.6M in Q3 2021.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.